Study finds, Recurrence Rate of Cystoid Macular Edema with T
A Study was conducted to investigate the rate of the recurrence of cystoid macular edema (CME) secondary to retinitis pigmentosa (RP) after the initiation of topical dorzolamide and the recurrence risk factors.

Researchers included patients who showed a treatment response to 1.0% topical dorzolamide. Topical dorzolamide treatment was continued during the follow-up. The recurrence of CME was evaluated at each follow-up visit. Risk factors for RP-CME recurrence were analyzed by Cox proportional hazards modeling.

--40 RP-CME patients showed a treatment response to topical dorzolamide.

--During the mean 3.9-yr follow-up, 14 patients exhibited recurrence; its rate was 15.6%, 34.7%, and 48.7% at 1, 3, and 5 years, respectively.

--A high baseline CST was significantly associated with recurrent.

In particular, the recurrence rate of RP-CME increased with time. A high baseline CST value was a risk factor for recurrent.